(Reuters) – The National Institutes of Health said on Thursday it began a study to evaluate the combination of antibiotic azithromycin and malaria drug hydroxychloroquine, which was previously touted by U.S. President Donald Trump as a “game changer”, for the treatment of COVID-19.
The study, for which Teva Pharmaceutical Industries Ltd will be donating medicines, will assess whether the combination can prevent hospitalization and death from COVID-19, the respiratory illness caused by the coronavirus.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
